Demonstration of a Capsule Plasmid in *Bacillus anthracis*

BRIAN D. GREEN,1 LAURIE BATTISTI,1 THERESA M. KOEHLER,1 CURTIS B. THORNE,1,* AND BRUCE E. IVINS2

Department of Microbiology, University of Massachusetts, Amherst, Massachusetts 01003,1 and U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 217012

Received 29 November 1984/Accepted 29 April 1985

Virulent and certain avirulent strains of *Bacillus anthracis* harbor a plasmid, designated pXO2, which is involved in the synthesis of capsules. Two classes of rough, unencapsulated (Cap−) variants were isolated from the capsule-producing (Cap+) Pasteur vaccine strains ATCC 6602 and ATCC 4229. One class was cured of pXO2, and the other class still carried it. Reversion to Cap+ was demonstrable only in rough variants which had retained pXO2. Proof that pXO2 is involved in capsule synthesis came from experiments in which the plasmid was transferred by CP-51-mediated transduction and by a mating system in which plasmid transfer is mediated by a *Bacillus thuringiensis* fertility plasmid, pXO12. Cells of *Bacillus cereus* and a previously unencapsulated (pXO2−) strain of *B. anthracis* produced capsules after the acquisition of pXO2.

*Bacillus anthracis* requires two virulence factors to cause disease. One of these is a toxin composed of three different proteins known as edema factor, lethal factor, and protective antigen (2, 10, 17). Mikesell et al. (7) and Robillard et al. (N. J. Robillard, T. M. Koehler, R. Murray, and C. B. Thorne, Abstr. Annu. Meet. Am. Soc. Microbiol. 1983, H54, p. 115) demonstrated that a 114-megadalton plasmid, formerly referred to as pBA1 but now designated pXO1, is associated with toxin production; Vodkin and Leppa (18) showed by cloning experiments that pXO1 carries the structural genes for protective antigen. The other virulence factor is a capsule composed of β-glutamyl polypeptide (6, 11, 16). When virulent strains of *B. anthracis* are grown on media containing serum or bicarbonate or both and incubated in a CO2-enriched atmosphere, they produce capsules and the colonies appear mucoid. In the absence of serum or bicarbonate, they fail to produce capsules and the colonies appear rough. Thus, colonies of mutants which cannot make capsules can be easily distinguished from colonies of the capsulated parental cells and are readily isolated by selection of rough sectors or outgrowth from mucoid colonies grown on media containing bicarbonate.

It was reported that the heat-attenuated Pasteur vaccine strains of *B. anthracis*, which form capsules but are avirulent because they are unable to produce toxin, were devoid of plasmid DNA (7). However, it has been shown recently that the Pasteur vaccine strains ATCC 6602 and ATCC 4229 do contain a capsule plasmid which has been designated pXO2 (B. D. Green, L. Battisti, and C. B. Thorne, Abstr. Annu. Meet. Am. Soc. Microbiol. 1985, H99, p. 124) and that the plasmid is present in all capsule strains of *B. anthracis* examined (B. E. Ivins and C. B. Thorne, Abstr. Annu. Meet. Am. Soc. Microbiol. 1985, H100, p. 124). Details of this work are presented here.

MATERIALS AND METHODS

Organisms. The organisms used in this study are listed in Table 1.

Media. NBY medium (pH 6.8) contained 8 g of nutrient broth (Difco Laboratories, Detroit, Mich.) and 3 g of yeast extract (Difco) per liter. For capsule production, NBY medium was supplemented with NaHCO3 (sterilized by filtration of a 9% solution) at a final concentration of 0.7% (wt/vol) and with horse serum (GIBCO Laboratories, Grand Island, N.Y.) at a final concentration of 10% (vol/vol). BHI medium contained 37 g of brain heart infusion (Difco) per liter. L broth contained 10 g of tryptone (Difco), 5 g of yeast extract (Difco), and 10 g of NaCl per liter with the pH adjusted to 7.0. R medium has been described previously (8). Phage assay medium contained the following (in grams per liter): nutrient broth (Difco), 8; CaCl2·2H2O, 0.15; MgSO4·7H2O, 0.2; MnSO4·H2O, 0.05; and NaCl, 5. The pH was adjusted to 6.0 with HCl. For solid medium, 15 g of agar was added per liter. Soft agar contained 5 g of agar per liter.

Immunassay agar plates contained 12 ml of R agar plus 2 ml of antiserum prepared in goats by immunization with viable spores of the Sterne strain of *B. anthracis*.

Capsule production. The ability of *B. anthracis* and *B. cereus* to produce capsules was determined by growing cells on R agar or on NBY agar containing bicarbonate and serum. Plates were incubated in the presence of 5 or 20% CO2 at 37°C for 24 to 48 h.

Toxin assays. Lethal factor and edema activities were assayed as described previously (7).

Detection of plasmid DNA. Plasmid DNA was extracted by a modification of the procedure described by Kado and Liu (3). Cells for plasmid extraction were grown in 250-ml Erlenmeyer flasks containing 25 ml of BHI broth. Cultures were incubated for 16 h at 37°C on a rotary shaker (100 to 160 rpm). Cells from 25 ml of culture were collected by centrifugation at 10,000 rpm in a Sorvall SS34 rotor for 10 min at 15°C and suspended in 1 ml of E buffer (0.04 M Tris-hydroxide [Sigma Chemical Co., St. Louis, Mo.], 0.002 M EDTA [tetrasodium salt; Sigma], 15% sucrose [pH 7.9]) by gentle vortexing. Cells were lysed by adding 1 ml of the suspension to 2 ml of lysis buffer prepared by adding 3 g of sodium dodecyl sulfate and 5 ml of 3 N NaOH to 100 ml of 15% (wt/vol) sucrose in 0.05 M Tris-hydroxide. The tubes were rapidly inverted 20 times to mix the cells and buffer and were then held in a 60°C water bath for 30 min. Pronase (0.5 ml; Calbiochem-Behring, La Jolla, Calif.) solution (2 mg/ml in 2 M Tris [pH 7.0]) was added, and the tubes were mixed as described above and incubated in a 37°C water bath for 20 min. The lysate was extracted with 6 ml of phenol-chloroform (1:1, vol/vol) by inverting the tubes 40 times. The
emulsions were separated by centrifugation at 10,000 rpm for 10 min at 15°C, and the aqueous phase was removed for electrophoresis.

Extracts (40 µl) were mixed with 10 µl of tracking dye (0.25% bromophenol blue, 15% Ficoll), and samples (40 µl) were applied to horizontal 0.7% agarose gels prepared and run in Tris-borate buffer (0.089 M Tris-hydroxide, 0.089 M boric acid, 0.0025 M EDTA [pH 8.2 to 8.3]). Electrophoresis was carried out at 70 V for 90 to 120 min at room temperature. Gels were stained with ethidium bromide (0.5 µg/ml in Tris-borate buffer).

**Plasmid curing.** Strains cured of pXO2 were found among spontaneous rough variants (see below) or isolated from cultures treated with novobiocin. For novobiocin treatment, 100–1000 CFU of *B. anthracis* was incubated into 250-ml flasks containing 50 ml of LB broth plus novobiocin (1 µg/ml) and incubated for 3 days at 37°C with gentle shaking. Cultures were diluted, and 0.1-ml samples were spread on plates of immuneassay agar and incubated at 37°C for 24 h in 5% CO2. Rough colonies of noncapsulated cells were isolated and tested for the loss of pXO2. Strains were cured of pXO1 by serial passage at 43°C (7, 15).

### Isolation of spontaneous rough mutants of *B. anthracis* 6602.

Cells were plated for single colonies on NBY agar containing bicarbonate and serum and incubated at 37°C in 20% CO2. After several days, rough outgrowth appeared at the edge of some of the mucoid colonies. The rough outgrowth was picked and purified by streaking on fresh plates of the same medium.

### Propagation and assay of bacteriophages.

Bacteriophage Wa (4) was obtained from *B. cereus* W (ATCC 11950). It was propagated on *B. anthracis* 6602 R1 (pXO2−) in soft overlays of phage assay agar incubated at 37°C for 17 to 20 h and was assayed against the same strain in soft overlays of phage assay agar incubated at 30°C. Bacteriophages CP-51 and CP-54 were propagated and assayed by methods described previously (9, 13, 14). *B. thuringiensis* subsp. *thompsoni* 4060 was the host for the propagation of CP-54. Phage lysates were routinely treated with DNase (50 µg/ml) to inactivate bacterial DNA, and they were confirmed to be free of bacterial contamination by plating samples on NBY agar.

### Isolation of Cap+ revertants of rough mutants.

To demonstrate reversion, ca. 105 spores of a rough mutant were

---

**Table 1. Strains used in this study**

<table>
<thead>
<tr>
<th>Strain*</th>
<th>Relevant characteristics*</th>
<th>Relevant plasmid(s)</th>
<th>Origin or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. anthracis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ames</td>
<td>Virulent, Cap+ Tox+</td>
<td>pXO1, pXO2</td>
<td>USDA*</td>
</tr>
<tr>
<td>Buffalo</td>
<td>Virulent, Cap+ Tox+</td>
<td>pX01, pX02</td>
<td>R. A. Packer</td>
</tr>
<tr>
<td>Colorado</td>
<td>Virulent, Cap+ Tox+</td>
<td>pX01, pX02</td>
<td>C. H. Chenesy</td>
</tr>
<tr>
<td>NHI</td>
<td>Virulent, Cap+ Tox+</td>
<td>pX01, pX02</td>
<td>USAMRIID*</td>
</tr>
<tr>
<td>Vollum 1B</td>
<td>Avirulent, Cap+ Tox+</td>
<td>pX02</td>
<td>This study</td>
</tr>
<tr>
<td>Vollum 1B VNR-1</td>
<td>Avirulent, Cap- Tox+</td>
<td>pX02</td>
<td>This study</td>
</tr>
<tr>
<td>Weybridge (Stere)</td>
<td>Avirulent, Cap+ Tox+</td>
<td>pX02</td>
<td>MRE*</td>
</tr>
<tr>
<td>Weybridge U444</td>
<td>Ind*</td>
<td>pX02</td>
<td>UV of Weybridge</td>
</tr>
<tr>
<td>Weybridge A</td>
<td>Colony variant of Weybridge</td>
<td>pX01</td>
<td>C. B. Thorne</td>
</tr>
<tr>
<td>Weybridge A UM23C1</td>
<td>Ura-, cured of pXO1</td>
<td>None</td>
<td>C. B. Thorne</td>
</tr>
<tr>
<td>Weybridge A UM23C1 tdl0</td>
<td></td>
<td></td>
<td>This study</td>
</tr>
<tr>
<td>4229 (Pasteur)</td>
<td>Avirulent, Cap+ Tox+</td>
<td>pX02</td>
<td>ATCC*</td>
</tr>
<tr>
<td>4229 UM12</td>
<td>Na+ Cap+</td>
<td>pX02</td>
<td>UV of 4229</td>
</tr>
<tr>
<td>4229 UM12 tr299-3</td>
<td>Na+ Cap+ Tc- Cry+</td>
<td>pX02, pXO12, pBC16</td>
<td>This study</td>
</tr>
<tr>
<td>6602 (Pasteur)</td>
<td>Avirulent, Cap+ Tox+</td>
<td>pX02</td>
<td>ATCC</td>
</tr>
<tr>
<td>6602 R1</td>
<td>Cap- Tox-</td>
<td>None</td>
<td>This study</td>
</tr>
<tr>
<td><strong>B. cereus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>569</td>
<td>Wild type</td>
<td></td>
<td>NRRL*</td>
</tr>
<tr>
<td>569 UM20</td>
<td>Ant*</td>
<td></td>
<td>UV of 569</td>
</tr>
<tr>
<td>569 UM20-1</td>
<td>Ant* Str*</td>
<td></td>
<td>UV of UM20</td>
</tr>
<tr>
<td>569 UM20-1 tdl0</td>
<td>Ant* Str* Cap+</td>
<td>pX02</td>
<td>This study</td>
</tr>
<tr>
<td>569 UM20-1 tr202-1</td>
<td>Ant* Str* Tc* Cry+</td>
<td>pX02, pXO12, pBC16</td>
<td>This study</td>
</tr>
<tr>
<td>569 UM20-1 tr305-1</td>
<td>Ant* Str* Tc* Cry* Cap+</td>
<td>pX02, pXO12, pBC16</td>
<td>This study</td>
</tr>
<tr>
<td>569 UM20-1 tr305-5</td>
<td>Ant* Str* Tc* Cry* Cap+</td>
<td>pX02, pXO12, pBC16</td>
<td>This study</td>
</tr>
<tr>
<td>11950</td>
<td>Carries bacteriophage Wa</td>
<td></td>
<td>ATCC</td>
</tr>
<tr>
<td><strong>B. thuringiensis subsp. thuringiensis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4042A UM8 tdl2</td>
<td>Ade- Cry+ Tc+</td>
<td>pXO12, pBC16</td>
<td>1</td>
</tr>
<tr>
<td><strong>B. thuringiensis subsp. thompsoni</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4060</td>
<td></td>
<td></td>
<td>NRRL</td>
</tr>
</tbody>
</table>

* In these strain designations, tr denotes a transient strain, and tdl denotes a transductant obtained by CP-51-mediated transfer of a plasmid.

* Abbreviations: Ade, adenine; Ant, antianthraxic acid; Cap, synthesis of capsule; Cry, synthesis of parasporal crystal; Ind, indole; Na+, nalidixic acid resistant; gtr*, streptomycin resistant; Tc-, pBC16-encoded tetracycline resistant; Tox+, synthesis of toxin; Ura, uracil.

* USDA, U.S. Department of Agriculture, Ames, Iowa.

* USAMRIID, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Md.


* UV, Mutagenesis by UV light (14).

* ATCC, American Type Culture Collection, Rockville, Md.

* NRRL, Northern Regional Research Laboratory, Peoria, Ill.

---

A. Green et al. *Infect. Immun.*
spread with 10⁶ PFU of phage Wo on NBY agar containing bicarbonate and serum. The plates were incubated at 37°C in 20% CO₂ for 2 days and examined for mucoid colonies.

Transduction of pXO2. Bacteriophage CP-51 was propagated on B. anthracis 6602 and assayed on B. cereus 569. Recipient cells for transduction were grown in 250-ml Erlehenmeyer flasks containing 25 ml of L broth (for B. cereus) or BHI broth with 0.5% (wt/vol) glycerol (for B. anthracis) and were incubated at 37°C on a rotary shaker at 250 rpm. Cells from a 10% (vol/vol) transfer of a 16-h culture were grown for 3 h. Cells (0.1 ml containing ca. 10⁶ CFU) and phage (0.1 ml containing ca. 5 × 10⁶ PFU) were spread together on NBY agar containing bicarbonate. Plates were incubated at 37°C in 20% CO₂. After 3 h, 0.1 ml of phage CP-54 (3 × 10⁶ PFU) was spread on the transduction plates to lyse noncapsulated cells and to allow the selection of capsulated transductants. Incubation in CO₂ was continued for 36 to 48 h.

Transfer of plasmids by mating. Matings were performed as described by Battisti et al. (1).

RESULTS

Plasmid analysis of B. anthracis strains. A number of virulent and avirulent strains of B. anthracis were analyzed for plasmid content. All virulent strains examined, which included NH, Ames, Colorado, Buffalo, and Vollum 1B, carried two plasmids, as shown in Fig. 1, lane 1, for Vollum 1B. In addition to pXO1, they contained a second, smaller plasmid which has been designated pXO2. Strains could be cured of pXO2 by growing them in the presence of novobiocin. A total of 3,000 to 5,000 colonies each of strains NH, Ames, and Vollum 1B obtained from cultures treated with novobiocin were screened for capsule formation and protective antigen synthesis on immunoassay agar. All colonies produced protective antigen, as evidenced by the halos surrounding them. However, ca. 1% of the colonies were rough (nonmucoid), indicating a failure to produce capsules. Two rough colonies of each strain were subcultured and examined for plasmid content and the capacity to synthesize toxin and capsules. These strains were designated Vollum 1B VNR-1 and VNR-2, NH NNR-1 and NNR-2, and Ames ANR-1 and ANR-2. They produced biologically active toxin, failed to produce capsules in 5 or 20% CO₂, and contained only one plasmid, pXO1 (Fig. 1, lane 5). They were identical to the toxigenic noncapsulated Weybridge (Sterne) veterinary vaccine strain with respect to phenotype and plasmid content (Fig. 1, lane 2).

The growth of toxigenic strains of B. anthracis at 43°C has been shown to result in the elimination of the toxin plasmid, pXO1 (7, 15). After virulent strains, including NH, Ames, and Vollum 1B, were cultured at 43°C, variants which were cured of pXO1 but still carried pXO2 were selected on immunoassay agar. Such variants, represented by a Pasteur vaccine strain (ATCC 6602) and Vollum 1B-1 in Fig. 1, lanes 3 and 4, produced no toxin. They synthesized capsules on R agar during growth in 20% CO₂ but not in 5% CO₂.

Isolation of rough (noncapsulated) variants of the Pasteur vaccine strains ATCC 6602 and ATCC 4229. When capsulated B. anthracis strains are grown on agar for several days under conditions conducive to capsule formation, mucoid colonies frequently have areas of rough outgrowth. Such areas of rough outgrowth have been shown to yield reverting and nonreverting noncapsulated mutants (5, 12). To demonstrate further a correlation between capsule formation and the presence of pXO2, we isolated spontaneous rough variants of B. anthracis 6602 and 4229. Figures 2 and 3 show the differences in colony and cell morphology between the wild-type mucoid strain and a rough variant of strain 6602 grown under conditions required for capsule formation. Strains 6602 and 4229, like virulent strains of B. anthracis, failed to produce capsules when grown in air (in the absence of bicarbonate and serum) and were indistinguishable in both colony and cell morphology from rough variants grown in either air or CO₂. Upon analysis of several rough variants for plasmid content, two classes were found. Some of them were cured of pXO2 and contained no detectable plasmid DNA (see Fig. 4, lane 3), and others still carried pXO2.

We reasoned that if pXO2 is involved in the formation of capsules, it should be possible to demonstrate reversion to
Cap" among rough variants which retain pXO2 but not among rough variants which are cured of the plasmid. Both classes of rough variants of strain 6602 were tested for reversion to Cap" by being exposed to bacteriophage Wa. The use of this phage, which can lyse noncapsulated cells but not capsulated cells, affords a convenient means of detecting small numbers of Cap" revertants in populations of Cap" cells (5). As predicted, no Cap" revertants were found among three independently isolated pXO2- variants, whereas Cap" revertants were found in each of three independently isolated rough strains which had retained pXO2.

Transduction of pXO2 with phage CP-51. Phage CP-51, propagated on B. anthracis 6002, was used to transduce pXO2 into B. cereus 569 UM20-1 Ant" Str" and B. anthracis Weybridge A UM23C1 (pXO1-, pXO2-) Ura". Phage CP-54, which is active on both B. cereus and B. anthracis, lysed noncapsulated cells but does not adsorb to capsulated cells (C. B. Thorne, unpublished data). Its application to transduction plates thus allowed the selection of Cap" transductants from a large population of Cap" cells. The frequency of Cap" transductants was ca. 10^{-8}PFU. Plasmid analysis, after clonal purification of Cap" transductants, revealed the presence of pXO2, which migrated in agarose gels at the same rate as pXO2 from strain 6602 (Fig. 4). The pXO2" B. cereus and B. anthracis transductants retained their respective auxotrophic markers, allowing positive identification. They produced capsules when grown in 20% CO2 on agar containing bicarbonate. Under such conditions, the mucoid colonies could not be distinguished from those of encapsulated cells of strain 6602. In the absence of bi-

![FIG. 3. Phase-contrast photomicrograph of cells of a B. anthracis Pasteur vaccine strain grown on bicarbonate agar in 20% CO2. (A) Strain 6602 (wild type). (B) Strain 6602 R1 (rough variant of 6602). Bar, 2.0 μm.](image)

![FIG. 4. Agarose gel electrophoresis of plasmid DNA demonstrating transduction of pXO2. Lanes: 1, B. anthracis 6602, Cap"; 2, B. anthracis 4229, Cap"; 3, B. anthracis 6602 R1, a Cap" pXO2- strain; 4, B. cereus 569 UM20-1, a recipient; 5, B. cereus 569 UM20-1 td10, a Cap" transductant; 6, B. anthracis Weybridge UM23C1, Cap", a recipient; 7, B. anthracis Weybridge UM23C1 td10, a Cap" transductant. c, pXO2. The faint bands above pXO2 are alternative forms of the plasmid.](image)
carbonate and CO₂, the colonies were rough and could not be distinguished from colonies of pXO2⁻ strains.

The size of pXO2, estimated to have a molecular mass of about 60 megadaltons based on its rate of migration in agarose gels, is probably very close to the maximum size of DNA that can be packaged by CP-51. Previously, a value of ca. 60 megadaltons was found for the molecular mass of CP-51 DNA (19).

Transfer of pXO2 to B. cereus by mating. To transfer pXO2 to B. cereus, we also made use of the Bacillus mating system in which plasmid transfer is mediated by the B. thuringiensis fertility plasmid, pXO12 (1). pXO12 was transferred from B. thuringiensis subsp. thuringiensis 4042A U8-2 to B. cereus 569 UM20-1 Strr. Tc⁺ transcipients of B. cereus were selected on L agar containing streptomycin (200 μg/ml) and tetracycline (25 μg/ml) and screened by phase microscopy for the presence of parasporal crystals, a phenotypic characteristic of pXO12⁺ cells (1). A B. cereus transcripient, 569 UM20-1 tr202-1, which inherited both pXO12 and pBC16, was then mated with B. anthracis 4229 UM12 Nalr, and Tc⁺ transcipients were selected on NBY agar containing tetracycline (5 μg/ml) and nalidixic acid (30 μg/ml). Approximately 50% of the Tc⁺ transcripients also inherited the fertility plasmid, pXO12. One of these, B. anthracis 4229 UM12 tr299-3 (pXO2, pXO12, pBC16), was used as the donor for transferring pXO2 to B. cereus 569 UM20-1. Mating mixtures were plated on NBY agar supplemented with bicarbonate, horse serum, streptomycin, and tetracycline. The plates were incubated in 20% CO₂. After 2 or 3 h, 0.1 ml of phage CP-54 (10⁶ PFU) was spread on some of the plates to lyse Cap⁺ Tc⁺ transcripients and to allow the selection of Cap⁺ Tc⁺ transcripients. Other plates were left untreated so that the total number of Tc⁺ transcripients could be scored. Incubation was continued for 24 h.

Mating mixtures yielded from 10⁴ to 10⁵ Tc⁺ transcripients per ml, and an average of 1 Tc⁺ colony out of 500 was mucoid and produced Cap⁺ cells on NBY agar plates containing bicarbonate and serum and incubated in CO₂. Plasmid analysis confirmed the presence of pXO2 along with pXO12 and pBC16 (Fig. 5). The Ant⁺ marker of the original B. cereus recipient was retained, and sporulating cells contained parasporal crystals characteristic of pXO12⁺ cells. Capsule production by a B. cereus pXO2⁺ transcripient is shown in Fig. 6 and 7. With respect to capsule formation, B. cereus cells that received pXO2 by mating could not be distinguished from those that received pXO2 by transduction. As with B. anthracis 6602 and 4229, capsules were produced by B. cereus only when cells carrying pXO2 were grown in CO₂.

### DISCUSSION

The results presented here demonstrate that plasmid pXO2 is involved in the formation of capsules by B. anthracis. All capsule-producing strains, both virulent and avirulent, examined thus far have been shown to harbor pXO2. Proof that pXO2 is involved in capsule synthesis was provided by experiments in which the plasmid was transferred by CP-51-mediated transduction or by the recently developed mating system for transferring plasmids among strains of B. anthracis, B. cereus, and B. thuringiensis (1). B. cereus 569, which is normally noncapsulated, produced capsules after the acquisition of pXO2 by either transduction or mating. Similarly, a noncapsulated strain of B. anthracis acquired the Cap⁺ phenotype when pXO2 was transferred to it by transduction.

Novobiocin was determined to cure strains of pXO2 selectively when both pXO1 and pXO2 were present. Approximately 1% of the colonies grown from novobiocin-treated cultures were cured of pXO2, but none of several thousand colonies was observed to be cured of the toxin plasmid, pXO1. All strains cured of pXO2 failed to produce capsules under conditions which normally promote capsule synthesis in pXO2⁴ strains.

When spontaneous rough variants were isolated from the...
avirulent Pasteur vaccine strains of *B. anthracis*, both pXO2+ and pXO2− types were found. Rough variants that retained pXO2 were able to revert to Cap+ but reversion of those cured of the plasmid could not be demonstrated. This observation explains earlier reports by Thorne (12) and Meynell (5) that some noncapsulated variants of *B. anthracis* were stable but that others were able to revert to Cap+. This also explains why the avirulent Weybridge (Sterne) vaccine strain, which produces toxin but not capsules, has not been observed to revert to the Cap+ virulent type. The Sterne strain carries pXO1 but not pXO2 and is therefore unable to revert to Cap+.

In view of the demonstration that rough variants which still carry pXO2 are able to revert to Cap+, it will be interesting to determine whether the mutations that engender the rough phenotype are chromosome or plasmid borne. We plan to test this by transferring pXO2 from rough pXO2+ variants to strains that have been cured of the plasmid.

ACKNOWLEDGMENTS

We thank C. D. Cox for his help in preparing the photographs. The portion of this work carried out at the University of Massachusetts was supported by contract DAMD17-80-C-0099 from the U.S. Army Medical Research and Development Command.

ADDITIONUM

After this manuscript was submitted for publication, the following paper, which confirms the presence of a capsule plasmid in *B. anthracis*, appeared: I. Uchida, T. Sekizake, K. Hashimoto, and N. Terakado, J. Gen. Microbiol. 131:363–367, 1985.

LITERATURE CITED

12. Thorne, C. B. 1960. Biochemical properties of virulent and